BR112017022032A2 - métodos para tratamento de transtornos de armazenamento lisossômico - Google Patents
métodos para tratamento de transtornos de armazenamento lisossômicoInfo
- Publication number
- BR112017022032A2 BR112017022032A2 BR112017022032A BR112017022032A BR112017022032A2 BR 112017022032 A2 BR112017022032 A2 BR 112017022032A2 BR 112017022032 A BR112017022032 A BR 112017022032A BR 112017022032 A BR112017022032 A BR 112017022032A BR 112017022032 A2 BR112017022032 A2 BR 112017022032A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- lysosomal storage
- storage disorders
- treating lysosomal
- compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
são descritos neste documento métodos que utilizam compostos de fórmula (i), (ia) e (ib) para tratar ou prevenir um transtorno de armazenamento lisossômico, métodos de fabricação de tais compostos e métodos de utilização de composições farmacêuticas e medicamentos contendo tais compostos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562147712P | 2015-04-15 | 2015-04-15 | |
PCT/US2016/027473 WO2016168420A1 (en) | 2015-04-15 | 2016-04-14 | Methods for treating lysosomal storage disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112017022032A2 true BR112017022032A2 (pt) | 2018-07-03 |
Family
ID=57126323
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112017022032A BR112017022032A2 (pt) | 2015-04-15 | 2016-04-14 | métodos para tratamento de transtornos de armazenamento lisossômico |
Country Status (9)
Country | Link |
---|---|
US (1) | US20180092923A1 (pt) |
EP (1) | EP3283477A1 (pt) |
AU (1) | AU2016250190A1 (pt) |
BR (1) | BR112017022032A2 (pt) |
CA (1) | CA2982769A1 (pt) |
MA (1) | MA42189A (pt) |
MX (1) | MX2017013281A (pt) |
TW (1) | TW201637655A (pt) |
WO (1) | WO2016168420A1 (pt) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8232073B2 (en) | 2009-01-02 | 2012-07-31 | Zacharon Pharmaceuticals, Inc. | Quantification of non-reducing end glycan residual compounds |
US9029530B2 (en) | 2009-01-02 | 2015-05-12 | Biomarin Pharmaceutical Inc. | Detection of oligosaccharides |
US8809009B2 (en) | 2009-01-02 | 2014-08-19 | Biomarin Pharmaceutical Inc. | Methods of diagnosing a disease and methods of monitoring treatment of a disease by quantifying a non-reducing end glycan residual compound and comparing to a second biomarker |
CN110325516A (zh) | 2016-12-29 | 2019-10-11 | 米尼奥尔克斯治疗有限公司 | 杂芳基化合物和它们的用途 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200630363A (en) * | 2004-11-10 | 2006-09-01 | Synta Pharmaceuticals Corp | Process for preparing trisubstituted pyrimidine compounds |
EP2030615A3 (en) * | 2007-08-13 | 2009-12-02 | ELFORD, Howard L. | Ribonucleotide reductase inhibitors for use in the treatment or prevention of neuroinflammatory or autoimmune diseases |
US20160367691A1 (en) * | 2013-06-06 | 2016-12-22 | Angiochem Inc. | Targeted enzyme compounds and uses thereof |
-
2016
- 2016-04-14 AU AU2016250190A patent/AU2016250190A1/en not_active Abandoned
- 2016-04-14 BR BR112017022032A patent/BR112017022032A2/pt not_active Application Discontinuation
- 2016-04-14 WO PCT/US2016/027473 patent/WO2016168420A1/en active Application Filing
- 2016-04-14 EP EP16780718.9A patent/EP3283477A1/en not_active Withdrawn
- 2016-04-14 MA MA042189A patent/MA42189A/fr unknown
- 2016-04-14 US US15/566,950 patent/US20180092923A1/en not_active Abandoned
- 2016-04-14 MX MX2017013281A patent/MX2017013281A/es unknown
- 2016-04-14 CA CA2982769A patent/CA2982769A1/en not_active Abandoned
- 2016-04-14 TW TW105111709A patent/TW201637655A/zh unknown
Also Published As
Publication number | Publication date |
---|---|
AU2016250190A1 (en) | 2017-11-02 |
TW201637655A (zh) | 2016-11-01 |
EP3283477A1 (en) | 2018-02-21 |
MX2017013281A (es) | 2018-01-26 |
US20180092923A1 (en) | 2018-04-05 |
CA2982769A1 (en) | 2016-10-20 |
MA42189A (fr) | 2018-04-18 |
WO2016168420A1 (en) | 2016-10-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112017003054A2 (pt) | compostos de aminopirimidinila como inibidores de jak | |
BR112015032595A2 (pt) | inibidores de ido | |
BR112018009252A2 (pt) | tratamento da osteoartrite | |
EA201891057A1 (ru) | Композиции и способы для ингибирования активности аргиназы | |
MX2016003486A (es) | Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades. | |
BR112017020999A2 (pt) | inibidores de indolamina-2,3-dioxigenase para o tratamento de câncer | |
BR112017003658A2 (pt) | composto, mistura, métodos para tratamento de uma doença e para inibição de uma glicosidase, e, composição farmacêutica. | |
CR20160564A (es) | Dinucleótidos cíclicos como moduladores de sting | |
NI201600071A (es) | Compuestos de inhibidor de autotaxina | |
BR112015022462A2 (pt) | inibidores de ido | |
EA201692079A1 (ru) | Ингибиторы лизин-специфической деметилазы-1 | |
BR112016029612A2 (pt) | compostos de di-hidroisoquinolinona substituídos | |
BR112014028042A2 (pt) | inibidores de nampt | |
EA201891251A1 (ru) | Бициклические ингибиторы pad4 | |
BR112015021999A8 (pt) | inibidores de indoleamina 2,3-dioxigenase (ido), seus usos, composição farmacêutica, e método para inibir a atiavidade de indoleamina 2,3-dioxigenase | |
MX2017004618A (es) | Inhibidores de la biosintesis de sulfato de heparano para el tratamiento de enfermedades. | |
BR112018005936A2 (pt) | inibidores de isoindolinona da interação de mdm2-p53 que têm atividade anticâncer | |
BR112017018092A2 (pt) | composto, composição farmacêutica, e, método para tratar e/ou prevenir uma doença ou distúrbio. | |
MX370270B (es) | Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades. | |
PH12018500446A1 (en) | Pyridinone dicarboxamide for use as bromodomain inhibitors | |
BR112017012504A2 (pt) | derivados de piperidina como inibidores de hdac1/2 | |
EA201692313A1 (ru) | Производные индолизина в качестве ингибиторов фосфоинозитид-3-киназ | |
CL2016001076A1 (es) | (aza) piridopirazolopirimidinonas e indazolopirimidinonas como inhibidores de fibrinolosis. | |
CL2014002661A1 (es) | Compuestos derivados de tienopirimidina o sus sales, como inhibidores de la alk quinasa; su proceso de preparacion; composicion farmaceutica que los comprende, util para el tratamiento del cancer. | |
PL410665A1 (pl) | Inhibitory arginazy oraz ich zastosowania terapeutyczne |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |